Citigroup
CYTH

Citigroup’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Citigroup’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,191
Closed -$2K – 6427
2022
Q2 		$2K Sell
1,191
-41
-3% -$99 ﹤0.01% 5935
2022
Q1 		$4K Buy
+1,232
New +$4.31K ﹤0.01% 5920

Other funds holding CYTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's CYTH Position: Q3 2022 in Review

Citigroup sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q3 2022, closing a stake of 1,191 shares — an estimated $2K sold.

Citigroup first reported a position in CYTH in Q1 2022 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 12 funds tracked by Wall St. Rank hold CYTH as of Q3 2022.

  • Citigroup reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 1,191 Cyclo Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2K.
  • Citigroup first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Citigroup's Cyclo Therapeutics, Inc. Common Stock position peaked at $4K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.